New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Ground Floor B Block
- Sir Charles Gairdner Hospital, Hospital Avenue
- Nedlands WA , 6009
MiReven was formed in 2010 through an investment from the Medical Research Commercialization Fund. The company is commercializing the pioneering work of Peter Leedman and Dr. Keith Giles at the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7. According to the company, miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor, as well as its associated signaling pathways that promote cancer development.